Genmab — November 2018
-
Mon finanstilsynet kunne tage sig sammen og kigge på det..
-
God morgen.
-
God morgen
-
The case is currently in pre-trial discovery, and a jury trial is scheduled to start in February 2019. The currently litigated patents are US 8,263,746, US 9,200,061 and US 9,758,590. In addition, Janssen, Genmab, Sanofi and Takeda opposed a European counterpart of the litigated U.S. patents, EP2511297. The patent was revoked in opposition proceedings. We appealed and the proceedings are currently pending.
-
-
Der sker et eller andet på tirsdag. Fra CC: And to give you further color on that, then let me briefly say something about the November 27 summary judgment. We cannot say too much about the process, but technically, the case could be over, then we get a positive judgment there.
-
repeat
from Q1 results conf call: as it relates to the court case with MorphoSys. It was a
level for me to comment on an active court case. And I can tell you that the economics of
the potential outcome of such a case are not on the public domain. But I can tell you that
the majority of the costs will be taken by Janssen, by our partner, so not by Genmab. And
that is contractually laid down, but not in a public doman.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind